Lablaboside C



Compound IDCDAMM02038
Common nameLablaboside C
IUPAC name6-[[8a-[4,5-dihydroxy-6-(hydroxymethyl)-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxycarbonyl-4-(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-5-[4,5-dihydroxy-6-(hydroxymethyl)-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxy-3,4-dihydroxyoxane-2-carboxylic acid
Molecular formulaC60H96O28

Experimental data

Retention time14.39
Adduct[M+2H]2+
Actual mz633.31
Theoretical mz633.312
Error4.23
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score6.3402

Identifiers and class information

Inchi keyBHKRIROTIBILJW-UHFFFAOYNA-N
SmilesO=C(O)C1OC(OC2CCC3(C)C(CCC4(C)C3CC=C5C6CC(C)(C)CCC6(C(=O)OC7OC(CO)C(O)C(O)C7OC8OC(C)C(O)C(O)C8O)CCC54C)C2(C)CO)C(OC9OC(CO)C(O)C(O)C9OC%10OC(C)C(O)C(O)C%10O)C(O)C1O
SuperclassLipids and lipid-like molecules
ClassPrenol lipids

Pharmacokinetic properties

Number of descriptor values(#stars)18
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)1
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)29
Number of reactive functional groups (#rtvFG)5
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)1265.4
Computed dipole moment(dipole)3.177
Total solvent accessible surface area (SASA)1330.36
Hydrophobic component of SASA (FOSA)835.301
Hydrophilic component of SASA (FISA)491.006
Pie component of the SASA (PISA)4.05
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)3141.71
Number of hydrogen bond donors (donorHB)15
Number of hydrogen bond acceptors (accptHB)43.8
Free energy of solvation of dipole (dip^2/V)0.0032127
Index of cohesive interaction in solids (ACxDN^.5/SA)0.127512
Globularity descriptor (glob)0.779784
Predicted polarizability in cubic angstroms (QPpolrz)100.995
Predicted hexadecane/gas partition coefficient (QPlogPC16)32.334
Predicted octanol/gas partition coefficient (QPlogPoct)81.494
Predicted water/gas partition coefficient (QPlogPw)65.003
Predicted octanol/water partition coefficient (QPlogPo/w)-3.259
Predicted aqueous solubility (QPlogS)-0.495
Conformation-independent predicted aqueous solubility (CIQPlogS)-6.03
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-3.307
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)0.055
Predicted brain/blood partition coefficient (QPlogBB)-6.568
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)0.016
Predicted skin permeability, log Kp (QPlogKp)-7.77
PM3 calculated ionization potential (IP(ev))9.43
PM3 calculated electron affinity (EA(eV))-0.955
Number of likely metabolic reactions (#metab)18
Prediction of binding to human serum albumin (QPlogKhsa)-2.611
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)0
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)423.714
Number of nitrogen and oxygen atoms (#NandO)28
Number of violations of Lipinski’s rule of five (RuleOfFive)3
Number of violations of Jorgensen’s rule of three (RuleOfThree)2

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P29350PTPN6Protein-tyrosine phosphatase 1CT98264SEA
P18031PTPN1Protein-tyrosine phosphatase 1BT16347SEA
P17706PTPN2T-cell protein-tyrosine phosphataseT49156SEA
P06746POLBDNA polymerase beta (by homology)T06958SEA
P13726F3Coagulation factor VII/tissue factorT72702SEA
P04746AMY2APancreatic alpha-amylaseT86918SEA
P16885PLCG2Phospholipase C-gamma-2T93922SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T16347DI0009Acute diabete complication[ICD-11: 5A2Y]P18031PTPN1
T16347DI0062Breast cancer[ICD-11: 2C60-2C6Y]P18031PTPN1
T16347DI0308Obesity[ICD-11: 5B80-5B81]P18031PTPN1
T16347DI0417Type 2 diabetes mellitus[ICD-11: 5A11]P18031PTPN1
T49156DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P17706PTPN2
T06958DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P06746POLB
T72702DI0075Cervical cancer[ICD-11: 2C77]P13726F3
T86918DI0110Cystic fibrosis[ICD-11: CA25]P04746AMY2A
T86918DI0328Pancreatic malfunction[ICD-11: DC30-DC3Z]P04746AMY2A

Copyright © 2025